With the risk of diversion potentially greater than it was before the pandemic, these data should be viewed as a warning sign.
Tom Knight, CEO, Invistics
Advertisement
Articles by Tom Knight, CEO, Invistics
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
Oral Semaglutide Show Promise as New Benchmark for Diabetes Care, Cardiovascular Protection
2
Limited Clinical Data Impact Cannabis Integration Into Standard Care | ASHP Midyear 2025
3
Opioid Overdose Deaths Fall by 34% in 2025 | ASHP Midyear 2025
4
Delgocitinib Improves Patients’ Chronic Hand Eczema
5
